Ultragenyx Pharmaceutical Inc.: shareholders and insiders

RARENASDAQHealthcare · Pharmaceutical Preparations

Price

$16.48

November 20, 2026Market cap $1.7B

What Ploutos Investor adds for Ultragenyx Pharmaceutical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 21, 2025 to Oct 19, 2026, from their own Form 4 filings.

9 Form 4s

Bought on the market

–

nobody

Sold on the market

$3.8M

9 people

From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan35%
  • The rest65%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $3.7M by 9 people

  • 2025: no buys, sold $115.0K by 2 people
  • 2026: no buys, sold $3.7M by 9 people
  • Oct 15, 2026Howard HornChief Financial Officer
    Kind
  • Sep 15, 2026Theodore Alan HuizengaSVP, Chief Accounting Officer
    Kind10b5-1
  • Sep 3, 2026Theodore Alan HuizengaSVP, Chief Accounting Officer
    Kind
  • Aug 3, 2026Karah Herdman ParschauerEVP and Chief Legal Officer
    Kind10b5-1
  • Aug 3, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Jul 1, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Jun 15, 2026Corazon (Corsee) D. SandersDirector
    Kind
  • Jun 15, 2026Karah Herdman ParschauerEVP and Chief Legal Officer
    Kind10b5-1
  • Jun 1, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • May 18, 2026Shehnaaz Suliman
    Kind10b5-1
  • May 5, 2026Eric CrombezEVP and Chief Medical Officer
    Kind
  • May 1, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Apr 1, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Mar 10, 2026Karah Herdman ParschauerEVP and Chief Legal Officer
    Kind
  • Mar 6, 2026Karah Herdman ParschauerEVP and Chief Legal Officer
    Kind
  • Mar 3, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Mar 2, 2026Eric CrombezEVP and Chief Medical Officer
    Kind
  • Mar 2, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Mar 2, 2026Howard HornChief Financial Officer
    Kind10b5-1
  • Mar 2, 2026Theodore Alan HuizengaSVP, Chief Accounting Officer
    Kind
  • Mar 2, 2026Karah Herdman ParschauerEVP and Chief Legal Officer
    Kind
  • Mar 2, 2026Emil D KakkisPresident & CEO
    Kind
  • Mar 2, 2026Erik HarrisEVP & Chief Commercial Officer
    Kind
  • Mar 2, 2026John Richard Pinion
    Kind
  • Feb 2, 2026Howard HornChief Financial Officer
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by RARE's officers and directors from 2014 up to November 20, 2025, 12 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

7 Holders over 5%Nov 10, 2026 Latest filing
  • Vanguard Portfolio Management
    Share of class8.60%
  • BlackRock, Inc.
    Share of class8.30%
  • RTW Investments, LPwith 1 more person
    Share of class7.90%
  • State Streetwith 1 more person
    Share of class7.60%
  • AQR Capital Management, LLCwith 1 more person
    Share of class6.66%
  • Madison Avenue International LPwith 5 more persons
    Share of class6.40%
  • Vanguard Capital Management
    Share of class5.13%
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 27, 202613G/A
  • FMR3.50%Feb 5, 202613G/A
  • Sands Capital Management4.70%Feb 12, 202513G/A
  • Wellington Management Group LLP2.70%Feb 10, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter+100%
  • Renaissance Technologies
    In the quarter
  • D.E. Shaw
    In the quarter-48%
  • Bridgewater (Dalio)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter+69%
  • AQR Capital
    In the quarter-90%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 19.8% of its shares outstanding were held short, -1.0% since the report before.

Shares held short
20.15M
19.8%
Since the report before20.35M on Sep 30, 2026
-1.0%
5.2
3.89M
More days to cover thanof 4,578 US-listed companies with enough volume
63%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 4.16M
  • Nov 15, 2023: Shares held short 3.50M
  • Nov 30, 2023: Shares held short 3.24M
  • Dec 15, 2023: Shares held short 3.34M
  • Dec 29, 2023: Shares held short 4.06M
  • Jan 12, 2024: Shares held short 4.12M
  • Jan 31, 2024: Shares held short 3.41M
  • Feb 15, 2024: Shares held short 3.56M
  • Feb 29, 2024: Shares held short 3.87M
  • Mar 15, 2024: Shares held short 3.78M
  • Mar 28, 2024: Shares held short 3.92M
  • Apr 15, 2024: Shares held short 4.38M
  • Apr 30, 2024: Shares held short 4.65M
  • May 15, 2024: Shares held short 4.34M
  • May 31, 2024: Shares held short 4.47M
  • Jun 14, 2024: Shares held short 5.04M
  • Jun 28, 2024: Shares held short 4.24M
  • Jul 15, 2024: Shares held short 4.36M
  • Jul 31, 2024: Shares held short 4.23M
  • Aug 15, 2024: Shares held short 3.85M
  • Aug 30, 2024: Shares held short 3.51M
  • Sep 13, 2024: Shares held short 3.61M
  • Sep 30, 2024: Shares held short 2.89M
  • Oct 15, 2024: Shares held short 3.16M
  • Oct 31, 2024: Shares held short 3.18M
  • Nov 15, 2024: Shares held short 3.35M
  • Nov 29, 2024: Shares held short 3.38M
  • Dec 13, 2024: Shares held short 3.71M
  • Dec 31, 2024: Shares held short 4.02M
  • Jan 15, 2025: Shares held short 4.25M
  • Jan 31, 2025: Shares held short 4.16M
  • Feb 14, 2025: Shares held short 4.28M
  • Feb 28, 2025: Shares held short 4.59M
  • Mar 14, 2025: Shares held short 4.81M
  • Mar 31, 2025: Shares held short 4.53M
  • Apr 15, 2025: Shares held short 5.46M
  • Apr 30, 2025: Shares held short 5.54M
  • May 15, 2025: Shares held short 5.89M
  • May 30, 2025: Shares held short 5.55M
  • Jun 13, 2025: Shares held short 6.08M
  • Jun 30, 2025: Shares held short 6.82M
  • Jul 15, 2025: Shares held short 8.80M
  • Jul 31, 2025: Shares held short 7.64M
  • Aug 15, 2025: Shares held short 8.41M
  • Aug 29, 2025: Shares held short 8.32M
  • Sep 15, 2025: Shares held short 7.95M
  • Sep 30, 2025: Shares held short 7.65M
  • Oct 15, 2025: Shares held short 8.69M
  • Oct 31, 2025: Shares held short 7.14M
  • Nov 14, 2025: Shares held short 7.83M
  • Nov 28, 2025: Shares held short 8.87M
  • Dec 15, 2025: Shares held short 8.60M
  • Dec 31, 2025: Shares held short 8.02M
  • Jan 15, 2026: Shares held short 8.86M
  • Jan 30, 2026: Shares held short 9.10M
  • Feb 13, 2026: Shares held short 9.86M
  • Feb 27, 2026: Shares held short 9.60M
  • Mar 13, 2026: Shares held short 9.93M
  • Mar 31, 2026: Shares held short 11.41M
  • Apr 15, 2026: Shares held short 12.09M
  • Apr 30, 2026: Shares held short 13.67M
  • May 15, 2026: Shares held short 13.98M
  • May 29, 2026: Shares held short 14.70M
  • Jun 15, 2026: Shares held short 14.31M
  • Jun 30, 2026: Shares held short 16.22M
  • Jul 15, 2026: Shares held short 13.44M
  • Jul 31, 2026: Shares held short 14.96M
  • Aug 14, 2026: Shares held short 15.89M
  • Aug 31, 2026: Shares held short 17.14M
  • Sep 15, 2026: Shares held short 16.57M
  • Sep 30, 2026: Shares held short 20.35M
  • Oct 15, 2026: Shares held short 20.15M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading35.2% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 35.2% of the shares in the reported trades were short sales, against 47.0% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
35.2%
The 14 beforeOct 14, 2026 – Nov 2, 2026
47.0%
Change
-11.8 pts
Short sales a dayon average, of 1.55M shares
547.8K
More than atof 3,666 US-listed companies, same days
11%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 40.5%
  • Oct 15, 2026: Short sales 42%
  • Oct 16, 2026: Short sales 40.2%
  • Oct 19, 2026: Short sales 39.6%
  • Oct 20, 2026: Short sales 47.9%
  • Oct 21, 2026: Short sales 48.7%
  • Oct 22, 2026: Short sales 39.9%
  • Oct 23, 2026: Short sales 49.2%
  • Oct 26, 2026: Short sales 66.4%
  • Oct 27, 2026: Short sales 56.7%
  • Oct 28, 2026: Short sales 50%
  • Oct 29, 2026: Short sales 37.7%
  • Oct 30, 2026: Short sales 46.8%
  • Nov 2, 2026: Short sales 42%
  • Nov 3, 2026: Short sales 41.2%
  • Nov 4, 2026: Short sales 44.5%
  • Nov 5, 2026: Short sales 33%
  • Nov 6, 2026: Short sales 25.9%
  • Nov 9, 2026: Short sales 35.2%
  • Nov 10, 2026: Short sales 44%
  • Nov 11, 2026: Short sales 43.6%
  • Nov 12, 2026: Short sales 26.4%
  • Nov 13, 2026: Short sales 39.9%
  • Nov 16, 2026: Short sales 46.4%
  • Nov 17, 2026: Short sales 12.4%
  • Nov 18, 2026: Short sales 34.7%
  • Nov 19, 2026: Short sales 32.4%
  • Nov 20, 2026: Short sales 40.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

3.71M Insiders' shares3.84% Of the company
  • Emil D KakkisPresident & CEO
    Directly659.0K
  • Thomas Richard KassbergCBO & EVP
    Directly265.2K
  • Eric CrombezEVP and Chief Medical Officer
    Directly111.2K
  • John Richard PinionSee Remarks
    Directly110.0K
  • Karah Herdman ParschauerEVP and Chief Legal Officer
    Directly92.6K
  • Erik HarrisEVP & Chief Commercial Officer
    Directly89.5K
  • Howard HornChief Financial Officer
    Directly89.2K
  • Theodore Alan HuizengaSVP, Chief Accounting Officer
    Directly67.9K
  • Shehnaaz SulimanDirector
    Directly28.0K
  • Corazon (Corsee) D. SandersDirector
    Directly21.1K
  • Matthew K FustDirector
    Directly14.9K

A lower bound: it counts only the 11 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

20 ETFs holding it1.14% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund1.14%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.63%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.23%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.11%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.10%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.10%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.09%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.09%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.08%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.05%

20 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

310 Managers, Q2 2026$3.6B Value of their positions
  • Q3 2025: Managers 304
  • Q4 2025: Managers 288
  • Q1 2026: Managers 301
  • Q2 2026: Managers 310

Institutional investors by quarter

The fund managers holding RARE, quarter by quarter, from Q1 2014 to Q2 2025, 46 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 310 managers held 107M shares, worth $3.6B. During the quarter 58 opened a position, 49 closed one, 113 added and 98 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+46%
  • Rtw Investments
    In the quarter+114%
  • Vanguard Portfolio Management
    In the quarter+26%
  • AQR Capital
    In the quarter+43%
  • State Street
    In the quarter+23%
  • Vanguard Capital Management
    In the quarter+2.5%
  • Two Sigma Investments
    In the quarter+64%
  • Sands Capital Management
    In the quarter-1.7%
  • Jacobs Levy Equity Management
    In the quarter+105%
  • Frontier Capital Management
    In the quarter+30%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Ultragenyx Pharmaceutical's filings show?

Who buys and sells is one part of Ultragenyx Pharmaceutical's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RARE's shareholders

Didn't find what you were looking for?

Ask us
Have RARE's insiders bought or sold?

From Jun 1, 2026 to Oct 19, 2026 Ultragenyx Pharmaceutical's insiders bought 0 and sold $655.0K of shares on the market. 76% of the sales were under set 10b5-1 plans.

Which well-known managers hold RARE?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $23M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.